common.study.topics.clinical

Viral Conjunctivitis Treatment Study

common.study.values.description

Viral Conjunctivitis Treatment Study

The objective of this study is to determine the efficacy AvenovaAR (0.01% hypochlorous acid) in the treatment of viral conjunctivitis. The investigators hypothesize that patients treated with AvenovaAR will have a quicker resolution of their ocular signs and symptoms of Viral Conjunctivitis compared with artificial tears.

common.study.values.location

participant.ui.study.affiliations-map.online-study.header-virtual

participant.ui.study.affiliations-map.online-study.text

participant.ui.study.affiliations-map.legend.locations participant.ui.study.affiliations-map.legend.selected

common.study.values.methods

No pharmaceutical medication involved common.study.methods.has-drugs-no
Patients and healthy individuals accepted common.study.methods.is-healthy-no

Device - 0.01% Hypochlorous acid

Randomized to treatment 0.01% Hypochlorous acid four times a day to the affected eye for 2 weeks. (Avenova is a FDA approved device)

Placebo

Placebo to be used four times a day to the affected eye for 2 weeks

participant.views.study.view.additional

participant.views.study.view.scientific-title

Avenova for the Treatment of Viral Conjunctivitis

common.study.values.clinical-trial-id

NCT03861728

participant.views.study.view.id

e73M8e